Stock Research: Evotec

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Evotec

GER:EVT DE0005664809
25
  • Value
    86
  • Growth
    3
  • Safety
    Safety
    51
  • Combined
    31
  • Sentiment
    35
  • 360° View
    360° View
    25
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Evotec SE is a drug discovery and development company. It operates in neuroscience, diabetes, oncology, infectious diseases, and respiratory diseases. Evotec SE operates in Germany. In the last fiscal year, the company had a market cap of $1,491 million, profits of $119 million, and revenue of $825 million, with 4827 employees.

more

ANALYSIS: With an Obermatt 360° View of 25 (better than 25% compared with alternatives), overall professional sentiment and financial characteristics for the stock Evotec are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Evotec. The consolidated Value Rank has an attractive rank of 86, which means that the share price of Evotec is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 86% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 51. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 35. Professional investors are more confident in 65% other stocks. The consolidated Growth Rank also has a low rank of 3, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 97 of its competitors have better growth. ...read more

more
Index
CDAX
NASDAQ
SDAX
TecDAX
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 76 15 6
Growth
3 8 89 63
Safety
Safety
51 44 36 12
Sentiment
35 1 16 49
360° View
360° View
25 10 20 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
47 27 78 34
Opinions Change
25 57 21 50
Pro Holdings
n/a 19 14 58
Market Pulse
29 7 29 55
Sentiment
35 1 16 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 76 15 6
Growth
3 8 89 63
Safety Safety
51 44 36 12
Combined
31 39 42 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
93 80 40 14
Price vs. Earnings (P/E)
82 1 6 1
Price vs. Book (P/B)
89 82 41 45
Dividend Yield
1 1 1 1
Value
86 76 15 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
25 65 78 60
Profit Growth
7 10 92 98
Capital Growth
38 4 16 12
Stock Returns
16 10 86 70
Growth
3 8 89 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
36 36 40 15
Refinancing
96 77 67 40
Liquidity
13 18 23 23
Safety Safety
51 44 36 12

Similar Stocks

Discover high‑ranked alternatives to Evotec and broaden your portfolio horizons.

Volkswagen VW

GER:VOW
Country: Germany
Industry: Automobile Manufacturers
Size: XX-Large
Full Stock Analysis

Vonovia

GER:VNA
Country: Germany
Industry: Real Estate: Operating Services
Size: X-Large
Full Stock Analysis

Drägerwerk

GER:DRW8
Country: Germany
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock is a good value with safe financing, but has low growth and negative sentiment. It is a good option for a cautious value investor looking for stability but who can tolerate low momentum and skeptical professional opinion.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: